Cooley advised RAPT Therapeutics, Inc. and Davis Polk & Wardwell advised the sales agents on the offering. RAPT Therapeutics, Inc. (Nasdaq:RAPT) announced the SEC-registered at-the-market offering of its common...
RAPT Therapeutics’ $150 Million At-The-Market Offering
Innoviz Technologies’ $65 Million Upsized Underwritten Follow-on Public Offering
Gornitzky represented the underwriters on the deal. Innoviz Technologies raised U.S. $65 million in upsized underwritten follow-on public offering of ordinary shares on Nasdaq. Innoviz is a global leader...
enCore Energy’s $70 million Sale of Common Shares
Dorsey & Whitney represented enCore, and Sidley Austin represented the agents in the offering. enCore Energy Corp. announced the establishment of a Controlled Equity Offering for the...
Verastem’s $85 Million Public Offering
Ropes & Gray advised Verastem, while Covington advised the underwriters in the offering. Verastem, Inc. announced its $85 million public offering of common stock and pre-funded warrants....
SI-BONE’s $83.05 Million Common Stock Offering
Cooley advised SI-BONE on the offering, and Latham & Watkins advised the underwriters involved. SI-BONE, Inc. has announced the pricing of its underwritten public offering of 3,775,000...
Vaxcyte’s $500 Million Public Offering
Cooley advises Vaxcyte on the offering, and Latham & Watkins advises the underwriters. Vaxcyte, Inc. (Nasdaq: PCVX) has announced the pricing of an underwritten public offering...
Longboard Pharmaceuticals’ $20 Million Common Stock Offering
Cooley advised Longboard Pharmaceuticals on the offering, and Latham & Watkins advised the underwriters involved. Longboard Pharmaceuticals, Inc. announced the pricing of its previously announced underwritten public...
Roivant Sciences’ $230 Million Common Shares Offering
Davis Polk & Wardwell represented Roivant Sciences, while Latham & Watkins represented the underwriters in the offering. Roivant Sciences (Nasdaq: ROIV) has announced its $230 million...
RAPT Therapeutics’ $75 Million Common Stock Offering
Cooley advised RAPT Therapeutics, while Davis Polk advised the joint book-running managers in the offering. RAPT Therapeutics, Inc. executed a $75 million SEC-registered follow-on offering of 4,054,055...
Roivant Sciences’ $150 Million Equity Offering
Davis Polk advised Roivant Sciences Ltd. in the deal, while Covington represented the underwriter, Cantor Fitzgerald. Roivant Sciences Ltd. announced its debut SEC-registered offering of 30,000,000...
Marinus Pharmaceuticals’ $60 Million Public Offering
Covington represented the underwriters on the deal. Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders,...
Vaxcyte’s $690 Million Public Offering
Cooley advised Vaxcyte, while Latham & Watkins represented the underwriters on the offering. Vaxcyte, a clinical-stage vaccine innovation company, announced its underwritten public offering of common stock and...